Lupus Nephritis Market
Number of pages: 100 | Report Format: PDF | Published date: February 24, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 1.9 billion |
|
Revenue Forecast in 2030 |
US$ 3.2 billion |
|
CAGR |
6.8% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Stages, Drug Class, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global lupus nephritis market was valued at US$ 1.9 billion in 2021 and is expected to register a revenue CAGR of 6.8% to reach US$ 3.2 billion by 2030.
Lupus Nephritis Market Fundamentals
Lupus nephritis (LN) develops when lupus autoantibodies attack waste-filtering mechanisms in the kidneys. LN is an autoimmune disease that occurs when the body’s immune system attacks its cells and organs. LN might progress to renal failure over time. LN is a kind of glomerulonephritis distinguished by the deposition of immune complexes in the glomeruli and inflammatory response in all kidney compartments. Inflammation causes persistent damage to the renal parenchyma and loss of kidney function over time.
LN is significantly more frequent in women than in men and occurs commonly during the childbearing years. LN affects nine out of every ten women. The disease is more frequent among African and Asian populations. One in every 250 Black American women in the United States is affected by LN. It is two to three times more common in African and Asian Americans than in white people.
Symptoms of LN include hematuria, proteinuria, high blood pressure, and swelling in ankles, hands, and feet. Diagnosis of LN involves urine tests followed by blood tests and kidney biopsy. In urine tests, physicians look for protein and blood in the urine. In blood tests, the levels of creatinine, a waste product produced by muscles, are identified. Moreover, a kidney biopsy is a procedure in which a small kidney section is observed under a microscope for inflammation or scarring.
[567567]
Lupus Nephritis Market Dynamics
The increasing prevalence of LN is the key factor driving the revenue growth of the lupus nephritis market. According to the estimates by American Kidney Fund in 2021, LN affects around 1.5 million people yearly. The disease affects about one in every two persons with the disease. The disease is more common in females. The prevalence of the disease is greater in adult non-Caucasian women, presumably due to genetic, environmental, and demographic variables. Recent research has shown that the prognosis and symptoms of lupus are strongly correlated with age. While lupus can occur at any age, the average age of diagnosis in adults is 24 to 32 years. Many studies discovered that American heritage is associated with higher LN-risk genes. Moreover, smoking, serum death decoy receptor 3, and TB are the secondary risk factors for developing LN. Additionally, exposure to pesticides used in homes and on farms, air pollution, and heavy metals may increase the chance of developing LN.
In the last decade, biologics (also known as biological medical therapy) has resulted in innovative and effective therapies for LN. Benlysta (belimumab) is one of many biologics evaluated in clinical studies for LN. Benlysta has been demonstrated to be both safe and effective when taken with conventional LN medications, reducing symptoms and minimizing adverse effects. Benlysta helps in reducing kidney functioning from becoming worse. According to the studies, Benlysta can lower autoantibody levels and assist in managing the symptoms of autoimmune diseases.
The global lupus nephritis market is expected to register growth at a significant pace throughout the projected period due to several medications that are under development. For instance, VIB4920, presently in Phase 2 of clinical trials, is sponsored by the National Institute of Allergy and Infectious Disease (NIAID). VIB4920 is a bioengineered protein that prevents immune cells from attacking one’s body, especially the kidneys, by inhibiting CD40L. In an early phase trial in LN or other disorders, VIB4920 was shown to be safe, acceptable, and effective.
However, the high cost of immunosuppressive drugs, coupled with their inaccessibility in low and middle-income nations, is anticipated to hamper the global lupus nephritis market revenue growth.
Lupus Nephritis Market Ecosystem
The global lupus nephritis market has been analyzed from four perspectives: stages, drug class, end user, and region.
Lupus Nephritis Market by Stages
[88776]
Based on stages, the global lupus nephritis market has been segmented into Class 1, Class 2, Class 3, Class 4, Class 5, and Class 6.
The International Society of Nephrology (ISN) and Renal Pathology Society (RPS) has classified LN mainly into six stages Class 1 (minimal mesangial lupus nephritis), Class 2 (mesangial proliferative lupus nephritis), Class 3 (focal lupus nephritis), Class 4 (diffuse lupus nephritis), Class 5 (membranous lupus nephritis), and Class 6 (advanced sclerosing lupus nephritis).
The Class 4 segment dominates the market with the largest revenue share. According to a meta-analysis evaluating the prevalence of biopsy-proven LN, the prevalence of the histological classes has remained stable over the last few decades, with class 4 accounting for almost 45%-50%. In Class 4 lupus nephritis, more than 50% of patients’ glomeruli are affected. The signs and symptoms of class 4 lupus nephritis include blood and/or excess protein in the urine and high blood pressure.
Lupus Nephritis Market by Drug Class
The global lupus nephritis market has been segmented based on drug class into immunosuppressive drugs, corticosteroids, and others.
The corticosteroids segment dominated the global lupus nephritis market with the largest revenue share in 2021. Most patients with active proliferative LN are initially treated with a pulse of an intravenous steroid followed by a high-dose oral steroid. Corticosteroids are effectual in treating mild LN with a reduced risk of developing renal impairment, such as minimal mesangial LN, mesangial proliferative LN, early focal LN, or membranous LN. Prednisone is the most common corticosteroid prescribed to treat LN. Furthermore, cyclophosphamide, mycophenolate, and azathioprine are also utilized as they enhance renal outcomes in individuals with aggressive renal lesions.
The immunosuppressive drugs segment is expected to show lucrative growth during the forecast years. Immunosuppressive drugs prevent the immune system from attacking healthy tissues of the body. Immunosuppressive works by interfering in the creation of DNA, the substance in cells that carries the blueprints of genetic information, to suppress the attack. High-intensity immunosuppression is used for the first three to six months, followed by MMF or azathioprine to regulate autoimmune and inflammation and stop flares. Moreover, the rising launch of new immunosuppressive drugs is also anticipated to increase the market growth during the forecast period. Saphnelo, by AstraZeneca, approved in 2021, is intended to treat an excess of interferon activation, which is crucial to the inflammation associated with lupus. This monoclonal antibody is a protein that searches for and binds to a particular kind of molecule, known as a cytokine, in the body.
Lupus Nephritis Market by End User
Based on end user, the global lupus nephritis market has been segmented into specialty clinics, hospitals, and others.
The hospitals segment dominated the global lupus nephritis market in 2021. This is due to the need for regular monitoring of the patient, as well as access to the latest medications and treatments at hospitals. In addition, hospitals are equipped with the necessary resources to provide comprehensive care and support to LN patients. This includes access to rheumatologists, who can help manage the disease, as well as provide support and advice. Furthermore, hospitals can provide a safe, secure environment for LN patients, which can help to reduce the risk of flare-ups and complications.
Lupus Nephritis Market by Region
Based on region, the global lupus nephritis market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America accounts for the largest revenue share of the global lupus nephritis market, due to factors such as rising incidences of LN, the presence of many top players, increasing healthcare standards, and accessibility to cutting-edge medical facilities in the region. The prevalence of LN among African Americans and Native-American females is rising.
The Europe lupus nephritis market revenue growth can be attributed to increased healthcare standards, high disposable incomes, growth in awareness about the disease, and increase in diagnostic activities for LN.
The market in Asia Pacific is anticipated to show high revenue growth during the forecast years, owing to increased government funding for research and development and their focus on improving healthcare standards. Moreover, the expansion of the medical tourism industry and improved per capita income levels are other factors expected to show profitable growth during the forecast period.
Lupus Nephritis Market Competitive Landscape
The prominent players in the global lupus nephritis market include:
Lupus Nephritis Market Strategic Developments
The high prevalence of the disease and increased research and development are the most prominent trends in the global lupus nephritis market.
AstraZeneca plc, F. Hoffman- La Roche AG, Novartis AG, and Bristol-Myers Squibb and Company are among the top market players.
The corticosteroid segment accounts for the largest revenue share of the lupus nephritis market.
North America is expected to register the highest revenue growth during the forecast period.
The high cost of drugs and their poor accessibility in middle-income countries are the most prominent restraints in the global lupus nephritis market.
*Insights on financial performance are subject to the availability of information in the public domain